TransMedics develops the Organ Care System (OCS), a portable perfusion technology that keeps donor organs functioning outside the body during transport to transplant centers. Its platforms cover heart, lung, and liver, aiming to extend preservation time and improve organ assessment versus traditional cold storage. Hospitals and transplant programs use the systems to expand usable donor organs and logistics options for time-critical transplants.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 157.4 | — | 34.9 | — |
| Q3 2025 | 143.8 | — | 24.3 | — |
| Q4 2025 | 160.8 | — | 105.4 | — |
| Q1 2026 | 173.9 | — | 7.3 | — |
| Q2 2026 | 189.9 | 20.7% | 14.7 | -57.9% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: HUTCHMED (China) Limited (HCM), Ethos Technologies Inc. (LIFE), Strive, Inc. (ASST), First Busey Corporation (BUSE), Beam Therapeutics Inc. (BEAM), OneSpaWorld Holdings Limited (OSW)